2 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow xuna: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT HQP1351( Olverembatinib dimesylate) - Prophylactic HQP1351 Therapy, Third Generation TKI | Phase 2 | Withdrawn | xuna | 2022-01-01 | 2023-01-18 | |
| Belimumab for Treatment of cGVHD Following Allo-HCT Belimumab (Benlysta) - cGVHD | Phase 1 / Phase 2 | Withdrawn | xuna | 2022-01-01 | 2023-01-18 |
belimumab (1) · olverembatinib (1)
China (2)